Lexaria Bioscience Corp. LXRP Archives - Page 5 of 27

FridayNov 01, 2019 11:06 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Proprietary Drug-Delivery System Featured in Peer-Reviewed Medical Journal

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed medical journal Advances in Therapy. (http://ibn.fm/PfnAA). An article discussing the company reads, “In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid-edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation…

ThursdayOct 24, 2019 10:05 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applauds FDA Forward-Looking Decision on Reduced Risk Tobacco Format

Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration ("FDA"), for the first time ever, has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway. According to the update, this pathway includes product categories that could benefit from Lexaria's technology. The FDA-authorized product format is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there is no need to spit. Significantly, because there is no combustion, heating…

WednesdayOct 23, 2019 12:37 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Strides with Patented DehydraTECH™ Drug Delivery Platform

Lexaria Bioscience Corp. continues to make progress in the patenting and development of its DehydraTECH™ platform Lexaria developed the patented DehydraTECH™ drug delivery platform as a safer alternative to inhalation of nicotine or cannabinoids DehydraTECH™ has been shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has levered innovation, research and development into operations in four market verticals: cannabis, hemp, nicotine, and pharmaceuticals. Lexaria already introduced the DehydraTECH™ drug delivery platform into commercial use and has a second-generation delivery platform ready for launch in 2020. Lexaria is the…

FridayOct 18, 2019 2:33 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Offers Alternative to Traditional Inhalation

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) platform works to deliver chemical compounds to the bloodstream at speeds similar to inhalation methods, offering an alternative to smoking. An article discussing the company further reads, “Lexaria’s noncombustion-based, noninhalation-based delivery method requires no chemicals or additives. . . . ‘We use a patented dehydration synthesis process to combine the nicotine with simple ingredients like sunflower oil in a unique way,’ CEO Chris Bunka told Forbes (http://ibn.fm/uCoMP). ‘It allows for the removal of the bitter taste often associated with nicotine without the need for artificial flavors that are often appealing to children.…

ThursdayOct 10, 2019 1:35 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Innovation Research Through Agreement with Altria

The program focuses on the pursuit of reduced risk oral nicotine products that make use of Lexaria’s patented DehydraTECH drug delivery platform DehydraTECH has been studied extensively and both human/animal trials confirm its ability to enhance active ingredient absorption in digestible products The current research could contribute to the development of oral nicotine products that would usher in a new era of reduced-risk nicotine use Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) provided an extensive update on advances in its research and development program with Altria Ventures Inc., an indirect wholly owned subsidiary of…

WednesdayOct 09, 2019 10:40 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Featured in Human CBD Study Results Published in Clinical Journal

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://ibn.fm/AYzRL) (http://ibn.fm/PfnAA). Published in Advances in Therapy, a peer-reviewed medical journal, the human clinical study evaluated CBD delivery and effectiveness using LXRP-patented, DehydraTECH(TM)-powered TurboCBD(TM) capsules. Key findings highlighted in the publication included the following: CBD in-plasma levels with the TurboCBD 90 mg dose were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes (p < 0.05); Only the TurboCBD 90 mg…

TuesdayOct 08, 2019 11:19 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Riding High on Potential Cannabis, Nicotine Uses of Patented Technology

Lexaria Bioscience is helping to revolutionize efforts to provide common drug substances in an ingestible method that avoids unhealthy practices such as inhaled smoking or vaping Lexaria’s DehydraTECH platform works to deliver the chemical compounds to the blood stream at speeds comparable to inhalation methods, providing the means for discrete use and avoiding frustrating waits for users with dependencies The company recently obtained a patent in Australia that recognizes DehydraTECH not only as a food and beverage platform, but also as a potential means of pharmaceutical use for combatting select illnesses As Canada prepares to introduce legalization of cannabis food…

TuesdayOct 08, 2019 10:10 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Provides R&D Program Update

Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today provided an update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECH(TM) technology. According to the update, most of the investigation and work within the first phase of the project underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) and Lexaria's majority owned subsidiary Lexaria Nicotine LLC is either complete or significantly underway, with imminent commencement of one remaining aspect. Results have been positive to date and support successful completion…

WednesdaySep 25, 2019 12:45 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://ibn.fm/Ljt7D). An article discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH provides an avenue for safer, less-conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare. . . .…

TuesdaySep 17, 2019 9:48 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human CBD Study Results Published in Peer Reviewed Clinical Journal

Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced the publication of final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECH(TM) powered TurboCBD(TM); capsules. According to the update results were published in the peer reviewed medical journal, Advances in Therapy, which focuses on clinical medicine and pharmaceutical research and has been published continually since 1984. Lexaria reported several key findings highlighted in the publication, including but not limited to: CBD in-plasma levels with the 90mg dose of TurboCBD were significantly higher than with the generic…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP